Candesartan

Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) [1][2][3].

Product Specifications

CAS Number

[139481-59-7]

Product Name Alternative

CV 11974

UNSPSC

12352005

Hazard Statement

H361

Target

Angiotensin Receptor; PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/candesartan.html

Concentration

10mM

Purity

98.50

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=C2C(N=C(OCC)N2CC3=CC=C(C4=CC=CC=C4C5=NNN=N5)C=C3)=CC=C1)O

Molecular Formula

C24H20N6O3

Molecular Weight

440.45

Precautions

H361

References & Citations

[1]Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362 (9386) :759-66.|[2]Nishimura Y, et al. Chronic peripheral administration of the angiotensin II AT (1) receptor antagonist candesartan blocks brain AT (1) receptors. Brain Res. 2000 Jul 14;871 (1) :29-38.|[3]Sonia Villapol, et al. Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology. 2012 Dec;37 (13) :2817-29.